Convenience and Combination Drugs Sustain Market Growth Even as Heart Failure Risk Looms Large on the Global DPP-IV Inhibitors Market
Epidemic spread of diabetes across the world, convenience of oral medication, and effectiveness of combination drugs despite studies linking risk of heart failures with the use of DPP-4 Inhibitors are poised to drive the global market for DPP-IV Inhibitors to reach US$10.6 billion by the year 2024 . Dipeptidyl Peptidase-IV (DPP4) inhibitors represent an important class of drugs in the treatment of Type 2 Diabetes mellitus. DPP-IV inhibitors, also called “gliptins”, inhibit the DiPeptidyl Peptidase IV (DPP-4) enzyme and enhance the action of its substrate, the incretin hormones, which then aid in increased insulin release and maintain appropriate glucose levels in the blood. Gliptins represent an attractive alternative to the first-line therapy of metformin for diabetes, especially in people who cannot tolerate biguanide metformin hydrochloride because of adverse gastrointestinal effects, and in whom metformin-only therapy is not effective. Sitagliptin (Januvia, Janumet), Vildagl...